טוען...
SUN-LB024 Elevation in Morning Glucose Level May Be a Signal for the Development of Immune Checkpoint Inhibitor (ICPi) Induced Autoimmune Diabetes Insulin
Unleashing the immune system by using immune checkpoint inhibitors (ICPi) has become a powerful tool in treating a broad spectrum of malignancies. However, increasing the immune response through ICPi therapy can also induce immune-related adverse effects (irAEs). Autoimmune diabetes is a significant...
שמור ב:
| הוצא לאור ב: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Endocrine Society
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553107/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-LB024 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|